| 1 |
Vincze A, Facskó R, Budai-Szűcs M, Katona G, Gyarmati B, Csorba A, Zelkó R, Nagy ZZ, Szente L, Balogh GT. Cyclodextrin-enabled nepafenac eye drops with improved absorption open a new therapeutic window. Carbohydr Polym 2023;310:120717. [PMID: 36925244 DOI: 10.1016/j.carbpol.2023.120717] [Reference Citation Analysis]
|
| 2 |
Jansook P, Loftsson T. Self-assembled γ-cyclodextrin as nanocarriers for enhanced ocular drug bioavailability. International Journal of Pharmaceutics 2022;618:121654. [DOI: 10.1016/j.ijpharm.2022.121654] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 3 |
Wang TZ, Guan B, Liu XX, Ke LN, Wang JJ, Nan KH. A topical fluorometholone nanoformulation fabricated under aqueous condition for the treatment of dry eye. Colloids Surf B Biointerfaces 2022;212:112351. [PMID: 35091382 DOI: 10.1016/j.colsurfb.2022.112351] [Reference Citation Analysis]
|
| 4 |
Soe HMSH, Sripetch S, Loftsson T, Stefánsson E, Jansook P. Effect of Soluplus® on γ-cyclodextrin solubilization of irbesartan and candesartan and their nanoaggregates formation. Pharm Dev Technol 2021;:1-10. [PMID: 34895036 DOI: 10.1080/10837450.2021.2017968] [Reference Citation Analysis]
|
| 5 |
Bouattour Y, Neflot-Bissuel F, Traïkia M, Biesse-Martin AS, Frederic R, Yessaad M, Jouannet M, Wasiak M, Chennell P, Sautou V. Cyclodextrins Allow the Combination of Incompatible Vancomycin and Ceftazidime into an Ophthalmic Formulation for the Treatment of Bacterial Keratitis. Int J Mol Sci 2021;22:10538. [PMID: 34638878 DOI: 10.3390/ijms221910538] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 6 |
Wu HH, Garidel P, Michaela B. HP-β-CD for the formulation of IgG and Ig-based biotherapeutics. Int J Pharm 2021;601:120531. [PMID: 33775727 DOI: 10.1016/j.ijpharm.2021.120531] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 7 |
Zhou X, Li X, Xu J, Cheng Y, Cao F. Latanoprost-loaded cyclodextrin microaggregate suspension eye drops for enhanced bioavailability and stability. Eur J Pharm Sci 2021;160:105758. [PMID: 33588044 DOI: 10.1016/j.ejps.2021.105758] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 8 |
Hughes PM, Shen J. Ocular Surface Anatomy and Physiology: Impact on Product Development. Ophthalmic Product Development 2021. [DOI: 10.1007/978-3-030-76367-1_2] [Reference Citation Analysis]
|
| 9 |
Aleo D, Saita MG, Spitaleri F, Sanfilippo C, Patti A. Degradation profile of nepafenac in aqueous solution and structural characterization of a novel degradation product. J Pharm Biomed Anal 2020;189:113432. [PMID: 32592943 DOI: 10.1016/j.jpba.2020.113432] [Reference Citation Analysis]
|
| 10 |
Mazet R, Yaméogo JBG, Wouessidjewe D, Choisnard L, Gèze A. Recent Advances in the Design of Topical Ophthalmic Delivery Systems in the Treatment of Ocular Surface Inflammation and Their Biopharmaceutical Evaluation. Pharmaceutics 2020;12:E570. [PMID: 32575411 DOI: 10.3390/pharmaceutics12060570] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 11 |
Meza-Rios A, Navarro-Partida J, Armendariz-Borunda J, Santos A. Therapies Based on Nanoparticles for Eye Drug Delivery. Ophthalmol Ther 2020;9:1-14. [PMID: 32383107 DOI: 10.1007/s40123-020-00257-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 12 |
Lorenzo-Veiga B, Diaz-Rodriguez P, Alvarez-Lorenzo C, Loftsson T, Sigurdsson HH. In Vitro and Ex Vivo Evaluation of Nepafenac-Based Cyclodextrin Microparticles for Treatment of Eye Inflammation. Nanomaterials (Basel) 2020;10:E709. [PMID: 32283583 DOI: 10.3390/nano10040709] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 13 |
Bíró, Aigner. Current Approaches to Use Cyclodextrins and Mucoadhesive Polymers in Ocular Drug Delivery—A Mini-Review. Sci Pharm 2019;87:15. [DOI: 10.3390/scipharm87030015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
|
